Episodes 1-15 of 796
Analysis of Patients With and Without AF Living With HFmrEF/HFpEF: FINEARTS-HF
CardiologyAnalysis of Patients With and Without AF Living With HFmrEF/HFpEF: FINEARTS-HF
Effect of Finerenone on NT-proBNP in HFmrEF/HFpEF: FINEARTS-HF Trial
CardiologyEffect of Finerenone on NT-proBNP in HFmrEF/HFpEF: FINEARTS-HF Trial
Kidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial
CardiologyKidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial
Mode of Death in Patients With HFmrEF/HFpEF: The FINEARTS-HF Trial
CardiologyMode of Death in Patients With HFmrEF/HFpEF: The FINEARTS-HF Trial
NYHA FC and Finerenone Response: Clinical Trial Insights
CardiologyNYHA FC and Finerenone Response: Clinical Trial Insights
Semaglutide improves walking distance, symptoms and QoL in patients with PAD and T2D
ACC Action CenterSemaglutide improves walking distance, symptoms and QoL in patients with PAD and T2D
Ticagrelor antidote restores platelet function in phase 3 study
ACC Action CenterTicagrelor antidote restores platelet function in phase 3 study
Complexities in ATTR-CM Care: Key Considerations for Accurate Diagnosis
Heart MattersComplexities in ATTR-CM Care: Key Considerations for Accurate Diagnosis
Advances in Care for ATTR-CM: Current and Emerging Strategies
Heart MattersAdvances in Care for ATTR-CM: Current and Emerging Strategies
Treating ATTR-CM: Current Strategies and Emerging Options
Heart MattersTreating ATTR-CM: Current Strategies and Emerging Options
Addressing Unmet Needs in ATTR-CM Care: Key Considerations for Optimal Management
Heart MattersAddressing Unmet Needs in ATTR-CM Care: Key Considerations for Optimal Management
Overcoming Challenges in ATTR-CM Care: Best Practices for Accurate Diagnosis
Heart MattersOvercoming Challenges in ATTR-CM Care: Best Practices for Accurate Diagnosis
Understanding the Pathophysiology Behind ATTR-CM
Heart MattersUnderstanding the Pathophysiology Behind ATTR-CM
Cost-Effectiveness of Universal vs. Selective Screening for ATTR-CM in HFpEF Patients
Heart MattersCost-Effectiveness of Universal vs. Selective Screening for ATTR-CM in HFpEF Patients
